Literature DB >> 3221326

The assessment of bioavailability in the presence of nonlinear elimination.

S D Hall1, C B McAllister, G R Wilkinson.   

Abstract

The simultaneous administration of an oral dose and intravenous tracer dose, as a method to determine bioavailability, was examined by means of computer simulation for drugs exhibiting Michaelis-Menten type elimination. A physiological pharmacokinetic model parameterized for man and including first-order absorption and elimination solely from the liver was employed. This tracer method provided good estimates of the true availability, with an error of 6% or less, over a wide range of dosing and dispositional conditions. Poorer estimates were noted when large doses of drugs with very short half-lives were considered. This poor performance was improved by administering the intravenous tracer at some time after the oral dose but an a priori basis for establishing this time was not apparent. The tracer method, therefore, appears to be a robust means of assessing, in man, oral bioavailability in the presence of Michaelis-Menten type elimination for drugs characterized by the general properties of the physiological model employed and with half-lives in excess of approximately 40 min. These findings together with the statistical power and simplicity of performance of the tracer method indicate that it is a valid technique for the assessment of bioavailability under a wide range of kinetic conditions.

Entities:  

Mesh:

Year:  1988        PMID: 3221326     DOI: 10.1007/bf01062137

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  21 in total

1.  Absolute bioavailability in man of N-acetylprocainamide determined by a novel stable isotope method.

Authors:  J M Strong; J S Dutcher; W K Lee; A J Atkinson
Journal:  Clin Pharmacol Ther       Date:  1975-11       Impact factor: 6.875

2.  Nonlinear assessment of phenytoin bioavailability.

Authors:  W J Jusko; J R Koup; G Alván
Journal:  J Pharmacokinet Biopharm       Date:  1976-08

3.  Statistical aspects of comparative bioavailability trials.

Authors:  W J Westlake
Journal:  Biometrics       Date:  1979-03       Impact factor: 2.571

4.  Hepatic tissue binding and the oral first-pass effect.

Authors:  P J Wedlund; G R Wilkinson
Journal:  J Pharm Sci       Date:  1984-03       Impact factor: 3.534

5.  Biological determinants of propranolol disposition in man.

Authors:  D M Kornhauser; A J Wood; R E Vestal; G R Wilkinson; R A Branch; D G Shand
Journal:  Clin Pharmacol Ther       Date:  1978-02       Impact factor: 6.875

6.  Critical evaluation of the potential error in pharmacokinetic studies of using the linear trapezoidal rule method for the calculation of the area under the plasma level--time curve.

Authors:  W L Chiou
Journal:  J Pharmacokinet Biopharm       Date:  1978-12

7.  Conversational SAAM--an interactive program for kinetic analysis of biological systems.

Authors:  R C Boston; P C Greif; M Berman
Journal:  Comput Programs Biomed       Date:  1981 Mar-Jun

8.  Simultaneous determination of the intravenous and oral pharmacokinetic parameters of D,L-verapamil using stable isotope-labelled verapamil.

Authors:  M Eichelbaum; A Somogyi; G E von Unruh; H J Dengler
Journal:  Eur J Clin Pharmacol       Date:  1981-01       Impact factor: 2.953

9.  Pharmacokinetics of ibuprofen.

Authors:  K S Albert; C M Gernaat
Journal:  Am J Med       Date:  1984-07-13       Impact factor: 4.965

10.  Theoretical consideration of drug distribution kinetics in a noneliminating organ: comparison between a "homogeneous (well-stirred)" model and "nonhomogeneous (tube)" model.

Authors:  T Terasaki; Y Sugiyama; T Iga; Y Sawada; M Hanano
Journal:  J Pharmacokinet Biopharm       Date:  1985-06
View more
  2 in total

1.  Pharmacokinetic analysis of mizolastine in healthy young volunteers after single oral and intravenous doses: noncompartmental approach and compartmental modeling.

Authors:  F Mesnil; C Dubruc; F Mentre; S Huet; A Mallet; J P Thenot
Journal:  J Pharmacokinet Biopharm       Date:  1997-04

2.  Hydralazine pharmacokinetics and interaction with food: an evaluation of the dog as an animal model.

Authors:  H A Semple; Y K Tam; R T Coutts
Journal:  Pharm Res       Date:  1990-03       Impact factor: 4.200

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.